AI-generated summary
The authors present a perspective and nonsystematic mini-review arguing that photobiomodulation therapy is an emerging, cost-effective option for cancer and complex eye and brain diseases. They describe a proposed paradigm shift in understanding how light interacts with cells, and conclude the therapy could raise standards of care. The abstract states the review was nonsystematic and does not report new patient data.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The authors describe this as a perspective and nonsystematic literature mini-review, so the conclusions rest on selected evidence rather than a systematic analysis.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Age-related macular degeneration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.